Publications by authors named "O Delpuech"

Claim this Profile
T
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Oona Delpuech

Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
Steven W Criscione, Matthew J Martin, Derek B Oien, Aparna Gorthi, Ricardo J Miragaia, Oona Delpuech

NPJ Precis Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells.
Matthew J Martin, Nicolas Floc'h, Matthias Pfeifer, Steven Criscione, Oona Delpuech

Cancer Res Commun· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.
Elizabeth A Kuczynski, Giulia Morlino, Alison Peter, Anna M L Coenen-Stass, Jennifer I Moss, Oona Delpuech

EMBO Mol Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Anna D Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Avinash Reddy, Oona Delpuech

Oncoimmunology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis